ClinicalTrials.gg
RecruitingNCT05278585PACE-TAVIUpdated Nov 29, 2023

Pacing the Atrium to Confirm or Exclude Pacemaker Indication in TAVI

An observational study in Aortic Valve Stenosis, sponsored by AZ Sint-Jan AV. Recruiting at 12 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by AZ Sint-Jan AV · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Aortic Valve Stenosis with a site in Belgium — 11 open to participants now, 14 under way, 1 of them phase 3. Aortic Valve Stenosis · Belgium.

Planned enrollment
11th of 20
500 · median 569
Started
2022
the only one that year
Observational
20 of 47
4 open now
Primary completion
2024-06
later than 1 of 13 live
Registered
36th of 47
by date

Among the 47 studies in Aortic Valve Stenosis with a site in Belgium, this one is the 11th largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2022, is one of 20 observational ones, reaches primary completion later than 1 of the 13 other live ones, and was the 36th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

11 of the 47 studies in Aortic Valve Stenosis with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Aortic Valve Stenosis with a site in Belgium, or all of them as a file.
02

Study summary

The current observational registry aims to evaluate in patients undergoing TAVI implantation:

  1. the positive and negative predictive value for PPM post TAVI of Wenckebach phenomenona (WB) during RAP during the TAVI procedure,
  2. baseline and procedural characteristics of TAVI-implantation associated with new conduction abnormalities and need for PPM implantation,
  3. peri-procedural safety, in-hospital and 1-month outcomes after TAVI implantation.
Read the detailed description

The persistent growth in transcatheter aortic valve implantation (TAVI) calls for optimized early discharge programs to handle the increasing patient load. While access site bleeding and stroke rate have decreased with improved technologies and operators' experience, acquired conduction abnormalities necessitating prolonged rhythm-monitoring and permanent pacemaker (PPM) implantation have remained largely unchanged, and even up to 39.9% for some TAVI platforms. Prompt identification of patients necessitating PPM implantation leads to optimal patient care and use of resources. Conversely, prompt identification of patients with low -to no- risk for PPM post TAVI shortens their hospitalization and facilitates early and safe discharge.

Several baseline characteristics such as age, preexistent right bundle branch block (RBBB) and the use of self-expanding valves are associated with post-TAVI PPM implantation, but more practical and clinically more relevant parameters are needed with high negative and positive predictive values that could support clinical decision-making.

En passant rapid atrial pacing (RAP) immediately following TAVI has recently been reported to be a valuable tool in PPM risk stratification. The absence of Wenckebach phenomena post implantation at RAP up to 120/' has a negative predictive value for PPM of 98.7%.2 First use of RAP in routine practice at AZ Sint Jan Brugge can confirm these first results (unpublished data). This technique improves our clinical assessment and identification of low-risk patients for PPM suitable for safe early discharge, as well as high-risk patients requiring further rhythm monitoring and eventual PPM implantation.

The current observational registry aims to evaluate in patients undergoing TAVI implantation:

  1. the positive and negative predictive value for PPM post TAVI of Wenckebach phenomenona (WB) during RAP during the TAVI procedure,
  2. baseline and procedural characteristics of TAVI-implantation associated with new conduction abnormalities and need for PPM implantation,
  3. peri-procedural safety, in-hospital and 1-month outcomes after TAVI implantation.
03

Conditions studied

  • Aortic Valve Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

500 patients in sinus rhythm undergoing TAVI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients in sinus rhythm with TAVI

Exclusion criteria

Exclusion Criteria:

  • Patients in atrial fibrillation at the time of the implantation
  • Patients with pre-existent pacemaker
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • RAP TAVI group

    All patients in sinus rhythm with TAVI

    Procedure: RAP TAVI

Interventions

  • ProcedureRAP TAVI

    All patients undergoing TAVI with no pre-existing pacemaker and in sinus rhythm at the time of the procedure will receive RAP by placing the temporary wire in the right atrium

06

What researchers measure

Primary outcomes

  1. Positive and negative predictive value of RAP for PPM implantation post TAVI

    Time frame: 1 month after TAVI

  2. Permanent pacemaker implantation

    Time frame: 1 month after TAVI

  3. New conduction abnormalities

    Time frame: within 1 week after TAVI

Secondary outcomes

  1. Duration of hospitalization

    Time frame: 1 month after TAVI

  2. Echocardiographic changes

    Time frame: 1 month after TAVI

  3. Stroke

    Time frame: 1 month after TAVI

  4. Major vascular bleeding

    Time frame: 1 month after TAVI

  5. New pericardial effusion

    Time frame: 1 month after TAVI

  6. All-cause mortality

    Time frame: 1 month after TAVI

07

Study locations

12 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Jun 2024, 21 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 21 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Mar 14, 2022
StartActual
Sep 1, 2022
Primary completionEst.
Jun 2024
CompletionEst.
Jun 2024
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05278585
Lead sponsor
AZ Sint-Jan AV
Responsible party
Ian Buysschaert, MD PhD (Principal Investigator, AZ Sint-Jan AV) — Principal investigator
First posted
Mar 14, 2022
Start date
Sep 1, 2022
Primary completion
Jun 2024 (estimated)
Completion
Jun 2024 (estimated)
Last update
Nov 29, 2023

Study contacts

Ian Buysschaert, MD, PhD
Contact
ian.buysschaert@azsintjan.be
+32050452670
Emma Christiaen, Msc
Contact
Emma.Christiaen@azsintjan.be
+32050453293
Ian Buysschaert, MD, PhD
principal investigator · AZ Sint Jan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion